Uncategorized
Aerpio completes phase 1b/2a study of novel DME agent
Aerpio Therapeutics has completed a phase 1b/2a study of a novel drug for diabetic macular edema, according to a press release.AKB-9778 is an inhibitor of human protein tyrosine phosphatase beta that works to activate Tie2, a receptor on vascular endothelial cells that stabilizes blood vessels, preventing abnormal blood vessel growth and vascular leak, the release said.